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Nucleus tractus solitariusThe aim of the present workwas to establish a time-course correlation between vascular and autonomic changes
that contribute to the development of hypertension during ethanol ingestion in rats. For this, male Wistar rats
were subjected to the intake of increasing ethanol concentrations in their drinkingwater during four weeks. Eth-
anol effects were investigated at the end of eachweek. Mild hypertension was already observed at the ﬁrst week
of treatment, and a progressive blood pressure increase was observed along the evaluation period. Increased
pressor response to phenylephrine was observed from ﬁrst to fourth week.α1-adrenoceptor protein in themes-
enteric bed was enhanced at the ﬁrst week, whereas β2-adrenoceptor protein in the aorta was reduced after the
second week. In the third week, ethanol intake facilitated the depressor response to sodium nitroprusside,
whereas in the fourth week it reduced nitrate content in aorta and increased it plasma. The bradycardic compo-
nent of the baroreﬂexwas impaired,whereas baroreﬂex tachycardiawas enhanced at the third and fourthweeks.
AT1A receptor and C-type natriuretic peptide (CNP)mRNAs in the nucleus tractus solitarius were increased at the
fourthweek. Theseﬁndings suggest that increased vascular responsiveness to vasoconstrictor agents is possibly a
link factor in the development and maintenance of the progressive hypertension induced by ethanol consump-
tion. Additionally, baroreﬂex changes are possibly mediated by alterations in angiotensinergic mechanisms and
CNP content within the brainstem, which contribute to maintaining the hypertensive state in later phases of
ethanol ingestion. Facilitated vascular responsiveness to nitric oxide seems to counteract ethanol-induced
hypertension.
© 2014 Elsevier Inc. All rights reserved.Introduction
Among several alcohol use-related disorders, it is well documented
in clinical and experimental studies that cardiovascular dysfunctions
and hypertension are associated with long-term ethanol consumption
(Chan et al., 1985; Corrao et al., 2004; Resstel et al., 2008). Indeed, pre-
clinical studies have demonstrated a positive correlation between the
duration of ethanol consumption and the development of hypertension
(Abdel-Rahman and Wooles, 1987; Resstel et al., 2006; Russ et al.,
1991).
Ethanol acts directly on blood vessels (Altura and Altura, 1987;
Puddey et al., 2001). Moreover, several mechanisms are thought to be
involved in ethanol-induced cardiovascular dysfunctions, includingology, School of Medicine of
P 14049-900, Brazil. Fax: +55
el).neuroendocrine changes and sympathetic nervous system activa-
tion (Chan et al., 1985; Da Silva et al., 2013; Resstel et al., 2008). Further-
more, clinical and experimental studies have demonstrated that long-
term ethanol exposure affects baroreﬂex activity (Abdel-Rahman
et al., 1985, 1987; Fazio et al., 2001; Resstel et al., 2006), and this effect
has been implicated in ethanol-induced hypertension (Russ et al.,
1991). Changes in baroreﬂex activity following chronic ethanol con-
sumption are mainly characterized by changes in the baroreﬂex con-
trol of the heart rate (HR) (Abdel-Rahman and Wooles, 1987; Abdel-
Rahman et al., 1985; Resstel et al., 2006), since baroreﬂex-mediated
changes in sympathetic nerve activity are not affected by ethanol
(Russ et al., 1991; Zhang et al., 1988). Although a central site of action
for ethanol-evoked baroreﬂex changes has been proposed (Li et al.,
2005; Varga and Kunos, 1992; Zhang et al., 1989), the mechanisms un-
derlying baroreﬂex changes are still poorly understood.
It has been demonstrated that ethanol-induced hypertension is also
followed by changes in vascular responsiveness to vasoactive agents
(Abdel-Rahman et al., 1987; Resstel et al., 2006; Tirapelli et al., 2008).
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adrenoceptor agonists in aorta rings and in segments of superior mes-
enteric arteries (Ladipo et al., 2002; Pinardi et al., 1992; Tirapelli et al.,
2006, 2008), whereas the relaxation response to acetylcholine is
impaired in these vessels (Husain, 2007; Tirapelli et al., 2007, 2008).
In vivo studies have also demonstrated that both, pressor response to
the α1-adrenoceptor agonist phenylephrine and hypotensive response
to the nitric oxide donor sodium nitroprusside (SNP), are facilitated
following long-term ethanol ingestion (Resstel et al., 2006; Russ et al.,
1991). Based on evidence that NO synthase (NOS) inhibition abolishes
the changes in vascular reactivity to vasoconstrictor and vasodilator
agents and that endothelial NOS (eNOS) protein levels and NO content
are reduced in the vessels of ethanol-treated animals (Husain, 2007;
Husain et al., 2011; Tirapelli et al., 2008), it is proposed that changes
in the vascular responsiveness are mediated by a reduced endothelial
NO formation.
Taken together, the evidencementioned above clearly demonstrates
that ethanol-induced hypertension is followed by changes in baroreﬂex
activity and vascular responsiveness to vasoactive agents. However,
most of the studies conducted so far have only evaluated hypertension
after long periods of ethanol exposure, when large blood pressure
changes are detected. Therefore, the mechanisms involved at the early
stages of hypertension development during ethanol exposure are un-
clear. Therefore, the main aim of the present study was to establish a
time-course correlation between baroreﬂex and vascular changes that
contribute to the development of hypertension during ethanol intake
in rats.
Material and methods
Animals and ethical approval
Male Wistar rats (250 g) were used in the present study. Animals
were housed collectively in plastic cages (4 per cage) in a temperature-
controlled room at 24 °C in the Animal Care Unit of the Department of
Physiology, School of Medicine of Ribeirão Preto, University of São
Paulo. They were kept under a 12:12 h light–dark cycle (lights on at
6 AM, lights off at 6 PM) and had free access to water and standard lab-
oratory food. Experimental procedures were carried out following pro-
tocols approved by the Ethics Committee for Animal Use of the School of
Medicine of Ribeirão Preto, and are in accordancewith the international
guidelines for animal use and welfare.
Ethanol treatment
Ethanol treatment regimen was based in a protocol previously re-
ported by our group (Da Silva et al., 2013; Resstel et al., 2008). Brieﬂy,
animals received increasing concentrations of ethanol in their drinking
water for fourweeks (ﬁrstweek: 5%, secondweek: 10%, third and fourth
weeks: 20% v/v). In the present study, animals were randomly divided
into four groups of control and ethanol-treated rats. Groups receiving
ethanol included: i) ﬁrst week ethanol: 5% ethanol in the drinking
water for one week; ii) second week ethanol: 5% ethanol for one week
followed by one week of 10% ethanol in the drinking water; iii) third
week ethanol: 5% ethanol for one week, one week of 10% ethanol, and
a third week of 20% ethanol in the drinking water; and iv) fourth week
ethanol: ﬁrst week 5% ethanol, second week 10% ethanol, and third
and fourth weeks 20% ethanol in the drinking water. Control groups re-
ceived water ad libitum for the same period that the ethanol-treated
groups.
Functional evaluation of cardiovascular activity
Surgical preparation and measurement of cardiovascular parameters.
Twenty-four hours before the trial, rats were anesthetized with
tribromoethanol (250 mg/kg, i.p.) and a catheter was inserted into theabdominal aorta through the femoral artery for cardiovascular record-
ing. A second catheter was implanted into the femoral vein for the infu-
sion of vasoactive agents to evoke arterial pressure changes. Both
catheterswere tunneled under the skin and exteriorized on the animal's
dorsum. After the surgery, rats were treated with a streptomycin and
penicillin polyantibiotic formulation (0.27 mg/kg, i.m.; Pentabiotico®;
Fort Dodge, Brazil) and received the non-steroidal anti-inﬂammatory
drug ﬂunixine meglumine (0.025 mg/kg, i.m.; Banamine®; Schering
Plough, Brazil) for postoperative analgesia.
On the trial day, the arterial cannula was connected to a pressure
transducer and the pulsatile arterial pressure was recorded using an
HP-7754A pre-ampliﬁer (Hewlett Packard, Palo Alto, CA, USA) and an
acquisition board (MP100A, Biopac Systems Inc, Goleta, CA, USA) was
connected to a personal computer. Systolic (SAP), mean (MAP) and di-
astolic (DAP) arterial pressure and heart rate (HR) values were derived
from pulsatile arterial pressure recordings.
Infusion of vasoactive agents. Intravenous infusion of the selective α1-
adrenoceptor agonist phenylephrine (50 μg/ml at 0.32 ml/min/kg) and
of the nitric oxide (NO) donor sodium nitroprusside (SNP) (70 μg/ml at
0.8 ml/min/kg) was performed using an infusion pump (K.D. Scientiﬁc,
Holliston,MA, USA) (Crestani et al., 2011; Resstel et al., 2006). Phenyleph-
rine and sodium nitroprusside caused incremental pressor and depressor
responses, respectively. Infusions of vasoactive drugs were randomized
and lasted for 30–40 s, resulting in the injection of a total dose of 8–
10 μg/kg of phenylephrine and 20–25 μg/kg of sodium nitroprusside.
Method of baroreﬂex evaluation. Baroreﬂex curves were constructed
matching MAP variations evoked by vasoactive agents with reﬂex HR
responses. Paired values of MAP and HR variations were plotted to cre-
ate sigmoid curves, which were used to determine baroreﬂex activity
(Crestani et al., 2010; Head and McCarty, 1987; Resstel et al., 2006).
Baroreﬂex analysis using sigmoid curves were characterized by ﬁve
parameters: (i) P1 (bpm), lower HR plateau; (ii) P2 (bpm), upper HR
plateau; (iii) HR range (bpm), difference between upper and lower
plateau levels; (iv) median blood pressure (BP50, mm Hg), mean ar-
terial pressure at 50% of the heart rate range; and (v) average gain
(G, bpm/mm Hg), average slope of the curves between +1 and −1
standard derivations from BP50. To analyze bradycardic and tachycardic
responses separately, HR valuesmatchingMAP changeswere plotted to
create linear regression curves and their slopes were compared to test
changes in baroreﬂex gain (Crestani et al., 2010; Resstel et al., 2006).
Dose–response arterial pressure curves. The graded rises and falls in
MAP evoked respectively by increasing concentrations of phenylephrine
and SNP were used to generate dose–response curves. In this manner, it
was possible to generate dose–response curves that demonstrated the
effect of ethanol treatment on pressor and depressor responsiveness
(Engi et al., 2012; Resstel et al., 2006). Dose–effect curveswere generated
for each vasoactive agent usingMAP values corresponding to cumulative
recording times (each 2 s) after starting the infusion. Themaximal effect
(Emax) and the dose at 50% of themean arterial pressure range (ED50) for
each vasoactive agent were compared in all experimental groups.
Experimental procedures. Independent groups of animals were evalu-
ated at the end of each week of the 4-week treatment protocol. For
this, 24 h before the trial, rats were subjected to surgical preparation
for cardiovascular recordings. In the trial day, animals were transferred
to the experimental room in their home box. They were allowed to
60 min adaptation to the experimental room conditions, such as sound
and illumination, before starting cardiovascular recordings. The experi-
mental room was temperature controlled (24 °C) and was acoustically
isolated from the other rooms. Cardiovascular recording was realized in
unanesthetized, freely moving rats. Animals in all experimental groups
were initially subjected to 30 min period of basal cardiovascular
Table 1
Number of animals in each group experimental (for each analysis).
Test Week 1 Week 2 Week 3 Week 4
Functional evaluation of cardiovascular activity 1
(blood pressure and HR baseline, baroreﬂex activity, vascular reactivity)
Control n = 6 n = 6 n = 6 n = 6
Ethanol n = 7 n = 6 n = 6 n = 6
Adrenoceptor protein levels in the mesenteric arterial bed and aorta 1
Control n = 6 n = 6 n = 6 n = 6
Ethanol n = 7 n = 7 n = 7 n = 8
Nitrate levels measurements 2
Control n = 8 n = 11 n = 10 n = 9
Ethanol n = 12 n = 11 n = 11 n = 10
NTS mRNA measurements 2
Control n = 9 n = 9 n = 9 n = 12
Ethanol n = 11 n = 10 n = 10 n = 10
1/2: Evaluations realized on the same set of animals.
247C.C. Crestani et al. / Toxicology and Applied Pharmacology 280 (2014) 245–255recording. In the sequence, they received intravenous infusion of phenyl-
ephrine and SNP, in a random order. At the end of the experiments, ani-
mals were euthanized by anesthetic overdose (urethane, 3 g/kg, i.p.).
Tissue sample collection and Western immunoblotting
At the end of each week of ethanol treatment, animals were eutha-
nized between 8 AM and 10 AM andmesenteric bed and aorta were re-
moved. Mesenteric bed and aorta were homogenized in RIPA buffer
(50 mM Tris, pH 8; 150 mM NaCl; 1 mM EDTA; 1% Triton x-100; 0.1%
SDS; 1% deoxycholate; 5 μg/ml aprotinin; 1 μg/ml leuptin; 1 mM
PMSF, 10.28 mM sodium orthovanadate, pH 10; 10.09 mM sodium py-
rophosphate; 100 mM sodium ﬂuoride). After incubation for 30 min at
4 °C, lysates were centrifuged (14,000 rpm, 15 min, 4 °C) and superna-
tants were collected and stored at−80 °C. The protein content in the
supernatant was determined by the method of Lowry (Lowry et al.,
1951).
Samples of 120 μg of protein were solubilized in sample buffer
(250 mM Tris, pH 6.8; 50% glycerol; 10%SDS, 500 mM DTT; 0.5%
bromophenol blue) for 5 min at 100 °C and subjected to SDS-PAGE
10% gel of electrophoresis and transferred onto nitrocellulose mem-
brane (Trans Blot, Bio-Rad Laboratories, Hercules, CA, USA). The mem-
branes were blocked by incubation with blocking buffer (10%BSA in
TBSt–1.6MNaCl and 0.2MTris, 0.1%Tween 20) for 2 h. After blocking,
blots were incubated overnight at 4 °C with primary antibodies to
α1a-adrenoceptor (1:1000 dilution; c-19, sc1477, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), β2-adrenoceptor (1:500 dilution; M-20,
sc-570, Santa Cruz Biotechnology), and β-actin (1:10,000 dilution;
13E5, Rabbit mAB #4970, Cell Signaling Technology). Then, blots were
washed and incubated with 1:5000 horseradish peroxidase-conjugated
IgG anti-rabbit (#7074, Cell Signaling Technology) or anti-goat (sc-
2768, Santa Cruz Biotechnology) secondary antibodies for 1 h at room
temperature. The immunoreactive bands were detected by ECL (Pierce,
Rockford, IL, USA). Blots were scanned with the ChemiDoc XRS Image
Analysis System (Bio-Rad Laboratories) and quantiﬁed by densitometry
with Quantity One Analysis software (Bio-Rad Laboratories). Protein
levels were normalized to β-actin.
Determination of nitrate content in plasma and aorta
Nitrate was determined by the NO/ozone chemiluminescence tech-
nique (Sievers 280 NO Analyzer, Bouder, CO, USA). For this, aorta was
homogenized in 0.4 M perchloric acid and 25 μl of lysate was collected.
Plasma sampleswere deproteinizedwith 95% ethanol (50 μl) for 30min
at−20 °C. Samples were centrifuged (10,000 rpm, 5 min, 4 °C) and su-
pernatants were used for measurement of nitrate, whereas the pellets
were reconstituted in distilled water for the determination of total pro-
tein concentrations. Sodium nitrate (Sigma, St. Louis, MO, USA) (5, 10,
15, 25, 50 and 100 μM) was used as standard reference. Nitrate levels
were normalized to protein content in samples.
Tissue sample collection, RNA extraction and semi-quantitative analysis of
mRNA expression by real-time PCR
In order to avoid an inﬂuence of anesthesia in the analysis of central
nervous system samples, awaken animalswere euthanized by decapita-
tion between 8 AM and 10 AM. After that, brains were quickly removed
and collected under RNAse-free conditions. Microdissections of the nu-
cleus tractus solitarius (NTS) were performed on 1200 μm-thick cryo-
stat sections using a stainless steel punch needle of 1.5 mm diameter,
corresponding to the coordinates 13.7–14.6 mm posterior to bregma,
in accordance with the Paxinos and Watson rat brain atlas (Paxinos
and Watson, 1997). All tissue samples were kept in the RNA later re-
agent (Ambion, Austin, TX), stored overnight at 4 °C and maintained
at−80 °C until extraction.Total RNA was isolated from each tissue sample using the TRIzol
reagent (Invitrogen, Auckland, New Zealand), according to the
manufacturer's instructions. The RNA concentration was determined
using a UV spectrophotometer, and 500 ng of RNAwas used for comple-
mentaryDNA synthesis using thehigh capacity complementaryDNA re-
verse transcription kit (Applied Biosystems, Foster City, CA, USA).
Semi-quantitative real-time PCR was performed using the Step One
Plus Real-Time PCR System (Applied Biosystems). The PCR reactions
were performed in triplicate and water was used as a negative control.
The quantitative expression of the type 1A angiotensin receptor
(AT1A), atrial natriuretic peptide (ANP) and C-type natriuretic peptide
(CNP) mRNAs, as well as three housekeeping genes (β-actin, GAPDH,
and 18S), was determined for each cDNA sample by speciﬁc assays
(TaqMan®, Applied Biosystems, USA). For each sample, the threshold
cycle (Ct) was measured and normalized to the mean of the three
housekeeping genes (ΔCt = CtUnknown− CtHousekeeping genes). The fold
change of mRNA in the unknown sample relative to the control group
was determined by 2−ΔΔCt, where ΔΔCt = ΔCtUnknown − ΔCtControl.
Therefore, data are presented as mRNA expression relative to the con-
trol group.
Drugs
Ethanol (Labsynth, Diadema, SP, Brazil) was diluted in the drinking
water. Phenylephrine hydrochloride (Sigma, St. Louis, MO, USA), sodi-
um nitroprusside dihydrate (Sigma), tribromoethanol (Sigma) and
urethane (Sigma) were dissolved in saline (0.9% NaCl). Flunixine
meglumine (Banamine®, Schering Plough, Brazil) and poly-antibiotic
preparation (Pentabiotico®, Fort Dodge, Brazil) were used as provided.
Data analysis
Data were expressed as mean ± standard error of the mean (SEM).
Results were compared using two-way ANOVA, with treatment and
time as independent factors, followed by Bonferroni's post hoc test. Re-
sults of statistical tests with P b 0.05 were considered signiﬁcant.
Results
Table 1 presents the number of animals in each analysis.
Time-course effect of ethanol ingestion in arterial pressure and heart rate.
Ethanol induced a progressive increase in arterial pressure (Fig. 1).
Analysis of MAP, SAP and DAP baseline indicated a signiﬁcant effect
of treatment (MAP: F(1,41) = 84, P b 0.0001; SAP: F(1,41) = 85,
P b 0.0001; DAP: F(1,41) = 68, P b 0.0001) and time (MAP: F(3,41) = 3,
P b 0.03; SAP: F(3,41) = 4, P b 0.01; DAP: F(3,41) = 3, P b 0.03), as well
as a treatment × time interaction (MAP: F(3,41) = 5, P b 0.006; SAP:
Fig. 1. Time-course of mean (MAP), systolic (SAP), and diastolic (DAP) arterial pressure; and heart rate (HR) in animals receiving water (control groups) or increasing concentration of
ethanol in drinking water (ﬁrst week: 5%, second week: 10%, third week: 20%, and fourth week 20% v/v). Circles represent the mean ± SEM. *P b 0.05 vs respective control group, two-
way ANOVA followed by Bonferroni's post hoc test.
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vealed that effect on MAP (week 1–week 4, P b 0.05), SAP (week 1–
week 4, P b 0.05) and DAP (week 1–week 4, P b 0.05) began at the
ﬁrstweek of treatment andwasmaintained during the entire evaluation
period (Fig. 1). Analysis of HR baseline did not indicate any effect of
treatment (F(1,41) = 1, P N 0.05) or time (F(3,41) = 0.1, P N 0.05) (Fig. 1).
Time-course effect of ethanol ingestion on pressor response to
phenylephrine and depressor effect of sodium nitroprusside
Phenylephrine. Intravenous infusion of the selectiveα1-adrenoceptor
agonist phenylephrine dose-dependently induced pressor responses
in all experimental groups (Fig. 2). Two-way ANOVA performed in
Emax of dose–response curves for phenylephrine indicated a signiﬁ-
cant effect of treatment (F(1,41)= 66, P b 0.0001), butwithout inﬂuence
of time (F(3,41) = 2, P N 0.05). Analysis also did not indicate a
treatment × time interaction (F(3,41) = 0.6, P N 0.05) (Fig. 2). Post hoc
analyses revealed that ethanol increased Emax of phenylephrine dose–
response curve at theﬁrst week of treatment and effect lasted the entire
evaluation period (week 1–week 4, P b 0.01) (Fig. 2). Analysis of ED50 of
dose–response curves did not indicate effects of either treatment
(F(1,41) = 2, P N 0.05) or time (F(3,41) = 0.3, P N 0.05) (Fig. 2).
Sodium nitroprusside. Systemic infusion of the nitric oxide donor SNP
dose-dependently reduced arterial pressure in all experimental groups
(Fig. 3). Analysis of Emax of dose–response curves for SNP indicated
signiﬁcant effect of treatment (F(1,41) = 29, P b 0.0001) and time
(F(3,41) = 11, P b 0.0001), as well as a treatment × time interaction
(F(3,41) = 3, P b 0.03) (Fig. 3). Post hoc analyses revealed that ethanol
consumption increased Emax of SNP dose–response curve at the third
(P b 0.01) and fourth (P b 0.001) weeks (Fig. 3). Analysis of ED50 did
not indicate effects of either treatment (F(1,41) = 3, P N 0.05) or time
(F(3,41) = 2, P N 0.05) (Fig. 3).
Time-course effect of ethanol ingestion on α1a- and β2-adrenoceptor
protein levels in the mesenteric arterial bed and aorta
α1a-adrenoceptor. Analysis of the α1a-adrenoceptor protein levels in
themesenteric arterial bed did not indicate the effect of either treatment(F(1,46) = 2, P N 0.05) or time (F(3,46) = 1, P N 0.05) (Fig. 4). Also, no
changes onα1a-adrenoceptor protein in the aorta were observed (treat-
ment factor: F(1,46) = 1, P N 0.05, time factor: F(3,46) = 0.3, P N 0.05)
(Fig. 4).
β2-adrenoceptor. Analysis of β2-adrenoceptor protein levels in the
mesenteric arterial bed did not show the effect of either treatment
(F(1,46) = 0.1, P N 0.05) or time (F(3,46) = 0.5, P N 0.05) (Fig. 4). Howev-
er, analysis of β2-adrenoceptor protein in the aorta indicated the effect
of treatment (F(1,46) = 20, P b 0.0001), but without inﬂuence of time
(F(3,46) = 3, P N 0.05). Analysis did not indicate a treatment × time in-
teraction (F(3,46) = 3, P N 0.05) (Fig. 4). Post hoc analyses revealed
that ethanol ingestion reduced β2-adrenoceptor protein in the aorta at
the second (P b 0.05), third (P b 0.01), and fourth (P b 0.05) weeks
(Fig. 4).
Time-course effect of ethanol ingestion on nitrate levels in the plasma and
aorta.
Plasma. Analysis of the nitrate levels in the plasma indicated the ef-
fect of treatment (F(1,74) = 12, P b 0.0008), but without inﬂuence of
time (F(3,74) = 1.5, P N 0.05). Analysis also did not indicate a
treatment × time interaction (F(3,74) = 2, P N 0.05) (Fig. 5). Post hoc
analyses revealed that ethanol ingestion increased nitrate levels in the
plasma at the fourth week (P b 0.05) (Fig. 5).
Aorta. Analysis of the nitrate levels in the aorta did not indicate any
effects of either treatment (F(1,74) = 3, P N 0.05) or time (F(3,74) = 1,
P N 0.05). However, post hoc analyses revealed that ethanol reduced ni-
trate in the aorta at the fourth week (P b 0.05) (Fig. 5).
Time-course effect of ethanol ingestion on baroreﬂex activity.
Nonlinear regression analysis of baroreﬂex activity indicated that eth-
anol consumption affected baroreﬂex curve parameters (Fig. 6 and
Table 2). There was a signiﬁcant effect of treatment (F(1,41) = 45,
P b 0.0001) and time (F(3,41) = 15, P b 0.0001), as well as a treatment ×
treatment interaction (F(3,41) = 12, P b 0.0001) in the gain (G) of
Fig. 2. (Left) Changes inmean arterial pressure (ΔMAP) evoked by increasing concentrations of the selective α1-adrenoceptor agonist phenylephrine in animals receiving water (control
groups) or increasing concentration of ethanol in drinkingwater (ﬁrst week: 5%, secondweek: 10%, thirdweek: 20%, and fourthweek 20% v/v). Circles represent themean± SEM. (Right)
Maximal effect (Emax) and dose at 50% of theMAP range (ED50) for phenylephrine dose–response curves. The bars represent themean± SEM. *P b 0.05 vs respective control group, two-
way ANOVA followed by Bonferroni's post hoc test.
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the P2 (F(1,41)=15, P b 0.0003) and BP50 (F(1,41)=7, P b 0.01) indicated
the effect of treatment, but without inﬂuence of time (P2: F(3,41) = 0.3,
P N 0.05; BP50: F(3,41) = 0.2, P N 0.05) (Fig. 6 and Table 2). There was no
signiﬁcant effect of either treatment (P1: F(1,41) = 0.5, P N 0.05; HR
range: F(1,41) = 3, P N 0.05) or time (P1: F(3,41) = 0.3, P N 0.05; HR
range: F(3,41) = 0.3, P N 0.05) in the P1 and HR range (Fig. 6 andTable 1). Post hoc analyses revealed that ethanol ingestion increased
the gain and P2 at the third (gain: P b 0.001, P2: P b 0.05) and fourth
(gain: P b 0.001, P2: P b 0.05) weeks (Fig. 6 and Table 2).
To further analyze the baroreﬂex activity, the effect of either MAP
increase or decrease on the HR was analyzed separately using linear re-
gression (Fig. 6 and Table 2). Analysis of bradycardiac response slopes
did not indicate a signiﬁcant effect of either treatment (F(1,41) = 1,
Fig. 3. (Left) Changes inmean arterial pressure (ΔMAP) evoked by increasing concentrations of the nitric oxide donor sodiumnitroprusside in animals receivingwater (control groups) or
increasing concentration of ethanol in drinking water (ﬁrst week: 5%, second week: 10%, third week: 20%, and fourth week 20% v/v). Circles represent the mean± SEM. (Right) Maximal
effect (Emax) and dose at 50% of theMAP range (ED50) for sodiumnitroprusside dose–response curves. The bars represent themean± SEM. *P b 0.05 vs respective control group, two-way
ANOVA followed by Bonferroni's post hoc test.
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treatment × treatment interaction (F(3,41) = 3, P b 0.02). Post hoc anal-
yses revealed that ethanol reduced the reﬂex bradycardia at the third
(P b 0.01) and fourth (P b 0.008) weeks (Fig. 6 and Table 2).
Analysis of tachycardiac response slopes indicated a signiﬁcant effect
of treatment (F(1,41) = 7, P b 0.01), but without inﬂuence of time
(F(3,41)=0.3, P N 0.05). Post hoc analyses revealed that ethanol increased
reﬂex tachycardia at the second week (P b 0.05) (Fig. 6 and Table 2).Time-course effect of ethanol ingestion on mRNA expression for AT1A
receptor, C-type natriuretic peptide, and atrial natriuretic peptide
in the NTS
AT1A receptor. Analysis of mRNA expression for the AT1A receptor
in the NTS indicated a signiﬁcant effect of treatment (F(1,71) = 12,
P b0.0008) and time (F(3,71) = 11, P b 0.0001), as well as a
treatment × time interaction (F(3,71) = 11, P b 0.0001) (Fig. 7). Post
Fig. 4. Time-course of relative protein levels (protein level/β-actin) of α1a- and β2-adrenoceptor in themesenteric arterial bed (left) and aorta (right) in animals receiving water (control
groups) or increasing concentration of ethanol in drinkingwater (ﬁrst week: 5%, secondweek: 10%, thirdweek: 20%, and fourthweek20% v/v). Circles represent themean±SEM. *P b 0.05
vs respective control group, two-way ANOVA followed by Bonferroni's post hoc test.
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NTS at the fourth week (P b 0.001) (Fig. 7).
CNP. Analysis of mRNA expression for CNP in the NTS indicated a
signiﬁcant effect of treatment (F(1,71) = 23, P b 0.0001) and time
(F(3,71) = 6, P b 0.002), as well as a treatment × time interaction
(F(3,71)= 9, P b 0.0001) (Fig. 7). Post hoc analyses revealed that ethanol
increased CNP mRNA in the NTS at the fourth week (P b 0.001) (Fig. 7).
ANP. Analysis of ANP mRNA expression in the NTS did not indicate
the effect of either treatment (F(1,71) = 2, P N 0.05) or time (F(3,71) =
0.3, P N 0.05) (Fig. 7).
Discussion
Table 3 summarizes the results obtained in this study. The develop-
ment of mild hypertension without alterations on resting HR during
ethanol consumption is consistent with previous clinical (Briasoulis
et al., 2012; Corrao et al., 2004) as well as experimental evidence
(Resstel et al., 2008; Russ et al., 1991). Arterial pressure elevation was
already observed at the ﬁrst week, and a progressive increase was
maintained during the entire evaluation period. The notion that theFig. 5. Time-course of nitrate levels in the plasma (left) and aorta (right) in animals receiving w
5%, secondweek: 10%, thirdweek: 20%, and fourthweek 20% v/v). Circles represent themean±
hoc test.hypertensive state can be already apparent in early stages of ethanol
consumption corroborates recent reports from our group (Da Silva
et al., 2013) and others (Utkan et al., 2001). However, present ﬁndings
contrast previous studies reporting that 4–8 weeks of ethanol con-
sumption are required to signiﬁcantly increase blood pressure (Abdel-
Rahman and Wooles, 1987; Strickland and Wooles, 1988). Blood etha-
nol content is a potential source of explanation for the disparity
among reports. For instance, Russ et al. (1991) reported blood ethanol
concentration of 22 mg/dl after four weeks of treatment, which was
not followed by blood pressure changes.We have recently documented
that blood ethanol content at the end of the fourthweek in our protocol
is ~600 mg/dl (Da Silva et al., 2013). Other important aspect to be con-
sidered is that directmeasurement of blood pressure in previous studies
was obtained in rats under anesthesia (Abdel-Rahman and Wooles,
1987; Russ et al., 1991). To our knowledge, this is the ﬁrst study to in-
vestigate the time-course of ethanol-induced hypertension through di-
rect blood pressure recording in unanesthetized animals.
We have recently reported a time-course of the blood ethanol con-
tent during our 4-week treatment protocol (Da Silva et al., 2013). A pro-
gressive increase in blood ethanol levels was observed from the ﬁrst to
the third week (ﬁrst week: 310 mg/dl; third week: 1418 mg/dl), but
values were smaller at the fourth week (612 mg/dl), thus indicating aater (control groups) or increasing concentration of ethanol in drinking water (ﬁrst week:
SEM. *P b 0.05 vs respective control group, two-way ANOVA followed by Bonferroni's post
Fig. 6. Nonlinear (top) and linear (bottom) regression analysis of the baroreﬂex correlating mean arterial pressure change (ΔMAP) and heart rate response (ΔHR) in animals receiving
water (control groups) or increasing concentration of ethanol in drinkingwater (ﬁrst week: 5%, secondweek: 10%, thirdweek: 20%, and fourthweek 20% v/v). Symbols on sigmoid curves
indicate the BP50. Circles represent the mean ± SEM on linear regression curves. Increase or decrease in the MAP was induced by the intravenous infusion of phenylephrine and sodium
nitroprusside, respectively.
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tained in our protocol at the end of the last week is similar to those
found in chronic alcohol abusers (300–500 mg/dl) (Cartlidge and
Redmond, 1990; Urso et al., 1981). Nevertheless, values reported by
us are higher than those previously reported in preclinical studies in
rodents (~200 mg/dl) (Husain et al., 2011; Tirapelli et al., 2006, 2008).
However, these earlier studies treated animals for longer periods
(5–13 weeks). In this sense, it is important to mention that although
a peak in blood ethanol content reached at the third week and levels
at the fourthweekwere smaller, we did not observe proportional differ-
ences in the quantity of ethanol ingested at the third (16 g/kg/day) and
fourth (14.8 g/kg/day) weeks (Da Silva et al., 2013). Taken together,
these results suggest that long-term ethanol consumption may induce
late pharmacokinetic changes that reduce systemic ethanol levels.
Baroreﬂex changes reported in the present study corroborate previ-
ous ﬁndings demonstrating that changes in baroreﬂex control of the
HR following chronic ethanol consumption are characterized by im-
paired reﬂex bradycardia, whereas baroreﬂex tachycardic response is
enhanced (Abdel-Rahman et al., 1985; Resstel et al., 2006). However,
earlier reports documented baroreﬂex changes before any increase in
arterial pressure occurred (Abdel-Rahman et al., 1985; Russ et al.,
1991), thus implying that impairment of baroreﬂex may constitute aTable 2
Parameters derived fromnonlinear (G, P1, P2, HR range and BP50) and linear (slope baroreﬂexbr
receiving water (control group) or increasing concentration of ethanol in drinking water (ﬁrst
Group G
(bpm/mm Hg)
P1
( bpm)
P2
( bpm)
HR
(bp
Week 1
Control −1.0 ± 0.08 −45 ± 7 71 ± 9 122
Ethanol −1.2 ± 0.10 −48 ± 7 75 ± 7 123
Week 2
Control −1.2 ± 0.07 −41 ± 5 66 ± 3 107
Ethanol −1.1 ± 0.1 −51 ± 5 82 ± 8 133
Week 3
Control −0.9 ± 0.06 −51 ± 5 65 ± 5 115
Ethanol −1.7 ± 0.10⁎ −40 ± 5 88 ± 6⁎ 128
Week 4
Control −1.3 ± 0.06 −57 ± 6 66 ± 1 124
Ethanol −1.9 ± 0.05⁎ −44 ± 1 89 ± 2⁎ 133
Values are mean ± SEM.
⁎ P 0.05 vs respective control group. Two-way ANOVA followed by Bonferroni's post hoc terelevant link factor in the hypertension development induced by etha-
nol ingestion. In the present study, arterial pressure was higher at the
ﬁrst week of treatmentwhile baroreﬂex changes occurred after the sec-
ondweek, indicating that baroreﬂex changes were secondary to hyper-
tension. Nevertheless, impairment of reﬂex bradycardiamay contribute
to maintain the hypertensive state at the third and fourth weeks.
Although the impairment of the baroreﬂex activity in hypertension ex-
tends to the reﬂex tachycardia (Grassi et al., 2006), the present results
do not support an involvement of changes in baroreﬂex tachycardia in
ethanol-induced hypertension. However, exacerbated tachycardic re-
sponse may be a risk factor for myocardial ischemia, sudden death
and cardiac failure (Dyer et al., 1980; Palatini and Julius, 1997).
Mechanisms underlying baroreﬂex changes evoked by long-term
ethanol consumption are still poorly understood. Some results provide
evidence for a role of morphological and functional changes in the NTS
(El-Mas and Abdel-Rahman, 2001; Wang and Abdel-Rahman, 2004),
which is the ﬁrst synaptic relay of the baroreﬂex pathway within the
central nervous system. The present study provides the ﬁrst evidence
of alterations in angiotensinergic mechanisms and CNP content within
theNTS of ethanol-treated rats. It has been demonstrated that angioten-
sin II acts in the NTS via AT1A receptor to attenuate baroreﬂex activity
(Campagnole-Santos et al., 1988; Matsumura et al., 1998). On theadycardia and slope baroreﬂex tachycardia) regression analysis of the baroreﬂex in animals
week: 5%, second week: 10%, third week: 20%, and fourth week 20% v/v).
range
m)
BP50
(mm Hg)
Slope bradycardia
(bpm/mm Hg)
Slope tachycardia
(bpm/mm Hg)
± 10 −7 ± 2 −1.3 ± 0.2 −2.1 ± 0.2
± 9 −8 ± 2 −1.5 ± 0.3 −2.0 ± 0.3
± 7 −6 ± 2 −1.2 ± 0.1 −1.8 ± 0.1
± 9 −10 ± 2 −1.5 ± 0.2 −2.5 ± 0.2⁎
± 9 −4 ± 3 −1.6 ± 0.1 −1.8 ± 0.2
± 6 −10 ± 2 −1.2 ± 0.1⁎ −2.3 ± 0.2
± 8 −4 ± 3 −1.7 ± 0.2 −1.8 ± 0.1
± 2 −12 ± 1 −1.0 ± 0.1⁎ −2.1 ± 0.1
st.
Fig. 7. Time-course of relative expression of AT1A receptor, C-type natriuretic peptide (CNP), and atrial natriuretic peptide (ANP) mRNAs within NTS in animals receiving water (control
groups) or increasing concentration of ethanol in drinkingwater (ﬁrst week: 5%, secondweek: 10%, thirdweek: 20%, and fourthweek20% v/v). Circles represent themean±SEM. *P b 0.05
vs respective control group, two-way ANOVA followed by Bonferroni's post hoc test.
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CNP, on baroreﬂex activity has been described (Thomas et al., 1999).
Therefore, our results provide evidence that increased expression of
AT1A receptor in the NTS may mediate the reduced reﬂex bradycardia
in ethanol-treated animals. The increased CNP in the NTS may explain
the enhanced baroreﬂex tachycardia, aswell as counteract an inhibitory
inﬂuence of local angiotensinergic mechanisms on reﬂex bradycardia. It
is important to note that CNP and AT1A mRNA changes were observed
only at the fourth week, thus indicating a possible involvement of addi-
tionalmechanisms in theNTS and/or other central autonomic regions in
baroreﬂex alterations observed before this period.
Recent ﬁndings demonstrated that transfection of AT1A receptors to
neurons in the NTS of mice lacking these receptors (AT1A−/−) caused a
sustained elevation in blood pressure, without affecting baroreﬂex and
autonomic activities (Abegaz et al., 2013). In addition to regulating
baroreﬂex activity and sympathetic outﬂow, central mechanisms of
cardiovascular regulation by angiotensin II also include stimulation of
vasopressin secretion (O'Callaghan et al., 2013). The increase in circulat-
ing vasopressin is an important mechanism involved in hypertension
following ethanol treatment (Resstel et al., 2008). Therefore, we cannot
exclude the possibility that increased AT1A receptor in the NTS could
contribute to ethanol-evoked hypertension by modulating vasopressin
release. Indeed, a role of the NTS in control of vasopressin release has
been reported (Blanch et al., 2013). The CNP acts centrally inhibiting va-
sopressin secretion induced by angiotensin II (Shirakami et al., 1993),
thus indicating that increased CNP in the NTS could counteract a facili-
tatory inﬂuence of local angiotensinergic mechanisms on vasopressin
release.Table 3
Summary of the effects of ethanol consumption.
First
week
Second
week
Third
week
Fourth
week
Cardiovascular baseline
Arterial pressure ↑ ↑ ↑ ↑
HR – – – –
Vascular function
Pressor response to phenyleprhine ↑ ↑ ↑ ↑
Depressor effect of sodium nitroprusside – – ↑ ↑
α1a-adrenoceptor (mesenteric bed) ↑⁎ – – –
α1a-adrenoceptor (aorta) – – – –
β2-adrenoceptor (mesenteric bed) – – – –
β2-adrenoceptor (aorta) – ↓ ↓ ↓
Nitrate—plasma – – – ↑
Nitrate—aorta – – – ↓
Autonomic function
Baroreﬂex bradycardia – – ↓ ↓
Baroreﬂex tachycardia – ↑ ↑ ↑
AT1A receptor—NTS – – – ↑
CNP—NTS – – – ↑
ANP—NTS – – – –
Up or down arrows indicate signiﬁcant increase or decrease, respectively.
⁎ Statistically nonsigniﬁcant but relevant (increase of 23%, P b 0.09).We observed that the hypotensive response induced by SNP was
enhanced at the third and fourthweeks, thus indicating enhanced vaso-
dilatation response. This result does not support an involvement of
changes in vascular reactivity to vasorelaxant agents in ethanol-
induced hypertension, since endothelial dysfunction in the hyperten-
sion is characterized by impairment in the action of NO and other
endothelium-derived relaxing agents (Tang and Vanhoutte, 2010).
However, facilitated vasodilatation response observed in the present
study may be an important mechanism counteracting ethanol-
induced blood pressure increase during later phases of hypertension
development.
The ethanol-induced facilitation of SNP depressor response corrobo-
rates previous results from our group (Resstel et al., 2006), as well as
studies carried out in isolated vessels demonstrating that chronic etha-
nol treatment increased the vasorelaxation response to acetylcholine
(Hatake et al., 1991; Utkan et al., 2001). By contrast, other studies
have reported that long-term ethanol ingestion may cause endothelial
dysfunction. Impairment of endothelial function induced by ethanol is
characterized by reduced modulatory action of endothelial NO, which
is mediated, at least in part, by down-regulation of the eNOS expression
(Husain, 2007; Tirapelli et al., 2008). Consistent with these results, we
observed reduction in the aortic nitrate content at the fourth week. It
is important to mention that NO reacts with superoxide anions to
form peroxynitrite (Kelm, 1999), which when protonated can give rise
to a strong oxidant. Oxidative stress is a key factor in ethanol-induced
vascular endothelial injury (Husain, 2007; Husain et al., 2011; Zima
et al., 2001). Therefore, the increase in plasmaNOevidenced in the pres-
ent study at the fourth week can contribute to reduction in aortic NO
content. However, we cannot exclude the possibility that reduced bio-
availability of aortic NO is due to an increased NO degradation. NO me-
tabolism results from its binding to molecules such as hemoglobin and
albumin or by an increased interactionwith superoxide anions andmo-
lecular oxygen (Kelm, 1999). Chronic ethanol induces erythrocytosis
and increases reactive oxygen species generation (Da Silva et al.,
2013; Husain et al., 2011; Zima et al., 2001). Taken together, these
data favor the idea that long-term ethanol ingestion reduces endothelial
NO production, which in turn could lead to enhanced vascular respon-
siveness to exogenous NO.
It has been demonstrated that cyclic guanosine monophosphate
(cGMP) formation in rat aortic strips induced by acetylcholine and
SNP is not affected by long-term ethanol consumption (Hatake et al.,
1994). Therefore, the hyper-responsivity to NO seems not to bemediat-
ed by an increased activity of the “soluble” guanylate cyclase (main NO
receptor). Thus, other down-stream components of NO pathways seem
to mediate the increased hypotensive response to SNP.
The facilitated pressor response to phenylephrine reported in the
present study is consistent with previous results in vivo (Resstel et al.,
2006; Russ et al., 1991), aswell as in vitro studies carried out in different
vessels (Pinardi et al., 1992; Tirapelli et al., 2007). An increase in phen-
ylephrine pressor response was already observed at the ﬁrst week and
maintained during the entire evaluation period, thus providing the
ﬁrst evidence that vascular responsivity to vasoconstrictor agents may
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duced by ethanol ingestion.
Ethanol-treated animals presented elevated levels of α1a-
adrenoceptor protein in themesenteric bed at the ﬁrst week, suggesting
that enhanced pressor response to phenylephrine in the early stages
of ethanol consumption is mediated by an up-regulation of α1-
adrenoceptor expression. However, changes observed in later phases
seem to be mediated by other mechanisms. The β2-adrenoceptor pro-
teinwas reduced in the aorta after the secondweek. Vasoconstrictor re-
sponse to phenylephrine is counteracted by β2-adrenoceptor (Davel
et al., 2012). Therefore, the reduced expression of β2-adrenoceptor
may contribute to the increase in phenylephrine pressor response in
later phases of ethanol consumption. Furthermore, a negative correla-
tion between the pressor response to phenylephrine and baroreﬂex
activity is proposed (Goldstein, 1983; Gordon et al., 1981). Thus, the in-
creased responsiveness to phenylephrine could be also related to the re-
duced baroreﬂex response to blood pressure increase evidenced at the
third and fourth weeks. Although a role of endothelium dysfunction in
the increased response to phenylephrine has been proposed (Husain,
2007; Tirapelli et al., 2008), present data provide evidence of a facilitat-
ed responsiveness to NO. Nevertheless, previous studies found higher
total intracellular-free Ca2+ increase responses to phenylephrine in
aortic vascular smooth muscle of ethanol-treated animals (Tirapelli
et al., 2006), indicating that increased mobilization of Ca2+ in vascular
smooth muscle cells could be also related to changes in phenylephrine
responsiveness.
In summary, the present results provide an advance in our under-
standing of the mechanisms associated with the development of
ethanol-induced hypertension. Our results show a progressive increase
in arterial pressure that is already evident at the onset of ethanol con-
sumption. Increased vascular responsiveness to vasoconstrictor agents
may contribute to the increase in blood pressure, possibly establishing
a link factor in thehypertension development induced by ethanol inges-
tion. Baroreﬂex changes were secondary to hypertension, but may con-
tribute to maintain the hypertensive state and the increased risk of
cardiac events in later stages of ethanol ingestion. The present study
provides the ﬁrst evidence of alterations in angiotensinergic mecha-
nisms and CNP content within the NTS of ethanol-treated rats, which
may be related to autonomic changes, as well as to neuroendocrine ef-
fects evoked by ethanol. Finally, facilitated vascular responsiveness to
NO seems to be an important mechanism counteracting ethanol-
induced hypertension during later phases of ethanol ingestion.Conﬂict of interest
The authors declare that there are no conﬂicts of interest.Acknowledgments
The authors wish to thank L.H.A. de Camargo and S. Guilhaume for
technical help. This work was supported by grants from the São Paulo
Research Foundation (individual PhD grant for Andreia Lopes da Silva
2009/51676-9, main researcher grant for Jose Antunes Rodrigues
2008/50611-8) and National Council for Scientiﬁc and Technological
Development (grant number 301827/2011/7).References
Abdel-Rahman, A.A., Wooles, W.R., 1987. Ethanol-induced hypertension involves impair-
ment of baroreceptors. Hypertension 10, 67–73.
Abdel-Rahman, A.R., Dar, M.S., Wooles, W.R., 1985. Effect of chronic ethanol administra-
tion on arterial baroreceptor function and pressor and depressor responsiveness in
rats. J. Pharmacol. Exp. Ther. 232, 194–201.
Abdel-Rahman, A.R., Merrill, R.H., Wooles, W.R., 1987. Effect of acute ethanol administra-
tion on the baroreceptor reﬂex control of heart rate in normotensive human volun-
teers. Clin. Sci. (Lond.) 72, 113–122.Abegaz, B., Davern, P.J., Jackson, K.L., Nguyen-Huu, T.P., Bassi, J.K., Connelly, A., Choong, Y.T.,
Allen, A.M., Head, G.A., 2013. Cardiovascular role of angiotensin type1A receptors in
the nucleus of the solitary tract of mice. Cardiovasc. Res. 100, 181–191.
Altura, B.M., Altura, B.T., 1987. Peripheral and cerebrovascular actions of ethanol, acetal-
dehyde, and acetate: relationship to divalent cations. Alcohol. Clin. Exp. Res. 11,
99–111.
Blanch, G.T., Freiria-Oliveira, A.H., Murphy, D., Paulin, R.F., Antunes-Rodrigues, J.,
Colombari, E., Menani, J.V., Colombari, D.S., 2013. Inhibitory mechanism of the nucle-
us of the solitary tract involved in the control of cardiovascular, dipsogenic, hormon-
al, and renal responses to hyperosmolality. Am. J. Physiol. Regul. Integr. Comp.
Physiol. 304, R531–R542.
Briasoulis, A., Agarwal, V., Messerli, F.H., 2012. Alcohol consumption and the risk of
hypertension in men and women: a systematic review and meta-analysis. J. Clin.
Hypertens. (Greenwich) 14, 792–798.
Campagnole-Santos, M.J., Diz, D.I., Ferrario, C.M., 1988. Baroreceptor reﬂexmodulation by
angiotensin II at the nucleus tractus solitarii. Hypertension 11, I167–I171.
Cartlidge, D., Redmond, A.D., 1990. Alcohol and conscious level. Biomed. Pharmacother.
44, 205–208.
Chan, T.C., Wall, R.A., Sutter, M.C., 1985. Chronic ethanol consumption, stress, and hyper-
tension. Hypertension 7, 519–524.
Corrao, G., Bagnardi, V., Zambon, A., La Vecchia, C., 2004. A meta-analysis of alcohol con-
sumption and the risk of 15 diseases. Prev. Med. 38, 613–619.
Crestani, C.C., Alves, F.H., Busnardo, C., Resstel, L.B., Correa, F.M., 2010. N-methyl-D-
aspartate glutamate receptors in the hypothalamic paraventricular nucleus
modulate cardiac component of the baroreﬂex in unanesthetized rats. Neurosci. Res.
67, 317–326.
Crestani, C.C., Tavares, R.F., Guimaraes, F.S., Correa, F.M., Joca, S.R., Resstel, L.B., 2011.
Chronic ﬂuoxetine treatment alters cardiovascular functions in unanesthetized rats.
Eur. J. Pharmacol. 670, 527–533.
Da Silva, A.L., Ruginsk, S.G., Uchoa, E.T., Crestani, C.C., Scopinho, A.A., Correa, F.M., De
Martinis, B.S., Elias, L.L., Resstel, L.B., Antunes-Rodrigues, J., 2013. Time-course of neu-
roendocrine changes and its correlation with hypertension induced by ethanol con-
sumption. Alcohol Alcohol. 48, 495–504.
Davel, A.P., Ceravolo, G.S., Wenceslau, C.F., Carvalho, M.H., Brum, P.C., Rossoni, L.V., 2012.
Increased vascular contractility and oxidative stress in beta(2)-adrenoceptor knock-
out mice: the role of NADPH oxidase. J. Vasc. Res. 49, 342–352.
Dyer, A.R., Persky, V., Stamler, J., Paul, O., Shekelle, R.B., Berkson, D.M., Lepper, M.,
Schoenberger, J.A., Lindberg, H.A., 1980. Heart rate as a prognostic factor for coronary
heart disease and mortality: ﬁndings in three Chicago epidemiologic studies. Am. J.
Epidemiol. 112, 736–749.
El-Mas, M.M., Abdel-Rahman, A.A., 2001. Effect of long-term ethanol feeding on brainstem
alpha(2)-receptor binding in Wistar–Kyoto and spontaneously hypertensive rats.
Brain Res. 900, 324–328.
Engi, S.A., Cruz, F.C., Leao, R.M., Correa, F.M., Planeta, C.S., Crestani, C.C., 2012. Effect of the
single or combined administration of cocaine and testosterone on cardiovascular
function and baroreﬂex activity in unanesthetized rats. J. Cardiovasc. Pharmacol. 59,
231–240.
Fazio, M., Bardelli, M., Macaluso, L., Fiammengo, F., Mattei, P.L., Bossi, M., Fabris, B.,
Fischetti, F., Pascazio, L., Candido, R., Carretta, R., 2001. Mechanics of the carotid artery
wall and baroreﬂex sensitivity after acute ethanol administration in young healthy
volunteers. Clin. Sci. (Lond.) 101, 253–260.
Goldstein, D.S., 1983. Arterial baroreﬂex sensitivity, plasma catecholamines, and pressor
responsiveness in essential hypertension. Circulation 68, 234–240.
Gordon, F.J., Matsuguchi, H., Mark, A.L., 1981. Abnormal baroreﬂex control of heart rate in
prehypertensive and hypertensive Dahl genetically salt-sensitive rats. Hypertension
3, I135–I141.
Grassi, G., Trevano, F.Q., Seravalle, G., Scopelliti, F., Mancia, G., 2006. Baroreﬂex function in
hypertension: consequences for antihypertensive therapy. Prog. Cardiovasc. Dis. 48,
407–415.
Hatake, K., Wakabayashi, I., Kakishita, E., Taniguchi, T., Ouchi, H., Hishida, S., 1991. Devel-
opment of tolerance to inhibitory effect of ethanol on endothelium-dependent vascu-
lar relaxation in ethanol-fed rats. Alcohol. Clin. Exp. Res. 15, 112–115.
Hatake, K., Wakabayashi, I., Taniguchi, T., Hishida, S., 1994. Increased endothelium-
dependent vascular relaxation in ethanol-fed rats. Alcohol. Clin. Exp. Res. 18,
1018–1023.
Head, G.A., McCarty, R., 1987. Vagal and sympathetic components of the heart rate range
and gain of the baroreceptor-heart rate reﬂex in conscious rats. J. Auton. Nerv. Syst.
21, 203–213.
Husain, K., 2007. Vascular endothelial oxidative stress in alcohol-induced hypertension.
Cell. Mol. Biol. (Noisy-le-grand) 53, 70–77.
Husain, K., Ferder, L., Ansari, R.A., Lalla, J., 2011. Chronic ethanol ingestion induces aortic
inﬂammation/oxidative endothelial injury and hypertension in rats. Hum. Exp.
Toxicol. 30, 930–939.
Kelm, M., 1999. Nitric oxide metabolism and breakdown. Biochim. Biophys. Acta 1411,
273–289.
Ladipo, C.O., Adigun, S.A., Nwaigwe, C.I., Adegunloye, B.J., 2002. Chronic ethanol consump-
tion alters vascular smooth muscle responses in rats. Clin. Exp. Pharmacol. Physiol.
29, 707–709.
Li, G., Wang, X., Abdel-Rahman, A.A., 2005. Brainstem norepinephrine neurons mediate
ethanol-evoked pressor response but not baroreﬂex dysfunction. Alcohol. Clin. Exp.
Res. 29, 639–647.
Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., 1951. Protein measurement with the
Folin phenol reagent. J. Biol. Chem. 193, 265–275.
Matsumura, K., Averill, D.B., Ferrario, C.M., 1998. Angiotensin II acts at AT1 receptors in
the nucleus of the solitary tract to attenuate the baroreceptor reﬂex. Am. J. Physiol.
275, R1611–R1619.
255C.C. Crestani et al. / Toxicology and Applied Pharmacology 280 (2014) 245–255O'Callaghan, E.L., Choong, Y.T., Jancovski, N., Allen, A.M., 2013. Central angiotensinergic
mechanisms associated with hypertension. Auton. Neurosci. 175, 85–92.
Palatini, P., Julius, S., 1997. Association of tachycardia with morbidity and mortality: path-
ophysiological considerations. J. Hum. Hypertens. 11 (Suppl. 1), S19–S27.
Paxinos, G., Watson, C., 1997. The Rat Brain in Stereotaxic Coordinates, 3 ed. Academic
Press, Sidney, Australia.
Pinardi, G., Brieva, C., Vinet, R., Penna, M., 1992. Effects of chronic ethanol consumption on
alpha-adrenergic-induced contractions in rat thoracic aorta. Gen. Pharmacol. 23,
245–248.
Puddey, I.B., Zilkens, R.R., Croft, K.D., Beilin, L.J., 2001. Alcohol and endothelial function: a
brief review. Clin. Exp. Pharmacol. Physiol. 28, 1020–1024.
Resstel, L.B., Tirapelli, C.R., Lanchote, V.L., Uyemura, S.A., de Oliveira, A.M., Correa, F.M.,
2006. Chronic ethanol consumption alters cardiovascular functions in conscious
rats. Life Sci. 78, 2179–2187.
Resstel, L.B., Scopinho, A.A., Lopes da Silva, A., Antunes-Rodrigues, J., Correa, F.M., 2008. In-
creased circulating vasopressin may account for ethanol-induced hypertension in
rats. Am. J. Hypertens. 21, 930–935.
Russ, R., Abdel-Rahman, A.R.,Wooles,W.R., 1991. Role of the sympathetic nervous system
in ethanol-induced hypertension in rats. Alcohol 8, 301–307.
Shirakami, G., Itoh, H., Suga, S., Komatsu, Y., Hama, N., Mori, K., Nakao, K., 1993. Central
action of C-type natriuretic peptide on vasopressin secretion in conscious rats.
Neurosci. Lett. 159, 25–28.
Strickland, J.A., Wooles, W.R., 1988. Effect of acute and chronic ethanol on the agonist re-
sponses of vascular smooth muscle. Eur. J. Pharmacol. 152, 83–91.
Tang, E.H., Vanhoutte, P.M., 2010. Endothelial dysfunction: a strategic target in the treat-
ment of hypertension? Pﬂugers Arch. 459, 995–1004.
Thomas, C.J., Head, G.A., Woods, R.L., 1999. Similar baroreﬂex bradycardic actions of atrial
natriuretic peptide and B and C types of natriuretic peptides in conscious rats. J.
Hypertens. 17, 801–806.
Tirapelli, C.R., Al-Khoury, J., Bkaily, G., D'Orleans-Juste, P., Lanchote, V.L., Uyemura, S.A., de
Oliveira, A.M., 2006. Chronic ethanol consumption enhances phenylephrine-induced
contraction in the isolated rat aorta. J. Pharmacol. Exp. Ther. 316, 233–241.Tirapelli, C.R., Leone, A.F., Coelho, E.B., Resstel, L.B., Correa, F.M., Lanchote, V.L., Uyemura, S.A.,
Padovan, C.M., de Oliveira, A.M., 2007. Effect of ethanol consumption on blood pressure
and rat mesenteric arterial bed, aorta and carotid responsiveness. J. Pharm. Pharmacol.
59, 985–993.
Tirapelli, C.R., Leone, A.F., Yogi, A., Tostes, R.C., Lanchote, V.L., Uyemura, S.A., Resstel, L.B.,
Correa, F.M., Padovan, C.M., de Oliveira, A.M., Coelho, E.B., 2008. Ethanol consumption
increases blood pressure and alters the responsiveness of the mesenteric vasculature
in rats. J. Pharm. Pharmacol. 60, 331–341.
Urso, T., Gavaler, J.S., Van Thiel, D.H., 1981. Blood ethanol levels in sober alcohol users
seen in an emergency room. Life Sci. 28, 1053–1056.
Utkan, T., Yildiz, F., Ilbay, G., Ozdemirci, S., Erden, B.F., Gacar, N., Ulak, G., 2001. Blood pres-
sure and vascular reactivity to endothelin-1, phenylephrine, serotonin, KCl and ace-
tylcholine following chronic alcohol consumption in vitro. Fundam. Clin. Pharmacol.
15, 157–165.
Varga, K., Kunos, G., 1992. Inhibition of baroreﬂex bradycardia by ethanol involves both
GABAAandGABAB receptors in the brainstemof the rat. Eur. J. Pharmacol. 214, 223–232.
Wang, X., Abdel-Rahman, A.A., 2004. An association between ethanol-evoked enhance-
ment of c-jun gene expression in the nucleus tractus solitarius and the attenuation
of baroreﬂexes. Alcohol. Clin. Exp. Res. 28, 1264–1272.
Zhang, X., Abdel-Rahman, A.R., Wooles, W.R., 1988. A differential action for ethanol on
baroreceptor reﬂex control of heart rate and sympathetic efferent discharge in rats.
Proc. Soc. Exp. Biol. Med. 187, 14–21.
Zhang, X., Abdel-Rahman, A.A., Wooles, W.R., 1989. Impairment of baroreceptor reﬂex
control of heart rate but not sympathetic efferent discharge by central neuro-
administration of ethanol. Hypertension 14, 282–292.
Zima, T., Fialova, L., Mestek, O., Janebova, M., Crkovska, J., Malbohan, I., Stipek, S.,
Mikulikova, L., Popov, P., 2001. Oxidative stress, metabolism of ethanol and alcohol-
related diseases. J. Biomed. Sci. 8, 59–70.
